Novo Nordisk, Xencor in antibody deal

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) and Xencor Inc. (NASDAQ:XNCR) partnered to use Xencor's XmAb bispecific Fc domain technology and XmAb immune inhibitor technology to develop antibodies against an undisclosed Novo target.

Xencor is eligible to receive up to $175 million including an undisclosed upfront payment, research support, and development, regulatory and sales milestones. Xencor also is eligible for royalties. ...